120
Participants
Start Date
November 30, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
August 31, 2027
Formoterol furmarate (20 μg)
Investigators chose to use the long-acting β2-AR agonist, formoterol, because of its efficacy and safety profile in patients with COPD and because formoterol showed the most association with protection from progression of CKD in our retrospective study.
Medical University of South Carolina, Charleston
Dialysis Clinic, Inc.
INDUSTRY
Medical University of South Carolina
OTHER